New hope for kids with tough neuroblastoma: combo therapy tested
NCT ID NCT07437963
First seen Mar 12, 2026 · Last updated May 24, 2026 · Updated 10 times
Summary
This study is for children and young adults (ages 1 to 30) with neuroblastoma that has returned, not responded, or worsened after prior treatment. It tests adding a drug called iberdomide to standard chemoimmunotherapy to see if it is safe and works better. The goal is to control the disease and improve response rates.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT NEUROBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.